Merck & Co. Forecast, price target & analysts
Merck & Co. Target price 2025 - Analyst rating & recommendation
Merck & Co. Classifications & Recommendation:
Merck & Co. Price Target
| Target Price | $102.00 |
| Price | $79.16 |
| Potential | 28.85% |
| Number of Estimates | 26 |
| 26 Analysts have issued a price target Merck & Co. 2026 . The average Merck & Co. target price is $102.00. This is 28.85% higher than the current stock price. The highest price target is $153.30 93.66% , the lowest is $82.82 4.62% . | |
| A rating was issued by 32 analysts: 20 Analysts recommend Merck & Co. to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Merck & Co. stock has an average upside potential 2026 of 28.85% . Most analysts recommend the Merck & Co. stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
26 Analysts have issued a sales forecast Merck & Co. 2025 . The average Merck & Co. sales estimate is $65.7b . This is 2.82% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $69.7b 9.11% , the lowest is $63.0b 1.49% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $64.2b | 6.74% |
|---|---|---|
| 2025 | $65.7b | 2.42% |
| 2026 | $69.5b | 5.77% |
| 2027 | $73.3b | 5.39% |
| 2028 | $74.4b | 1.61% |
| 2029 | $72.1b | 3.18% |
| 2030 | $68.9b | 4.45% |
| 2031 | $67.7b | 1.68% |
| 2032 | $68.8b | 1.67% |
14 Analysts have issued an Merck & Co. EBITDA forecast 2025. The average Merck & Co. EBITDA estimate is $30.4b . This is 15.80% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $34.1b 29.89% , the lowest is $28.0b 6.76% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $27.9b | 11.47% |
|---|---|---|
| 2025 | $30.4b | 8.94% |
| 2026 | $33.1b | 9.00% |
| 2027 | $35.6b | 7.33% |
| 2028 | $37.2b | 4.53% |
| 2029 | $36.5b | 1.88% |
| 2030 | $29.8b | 18.41% |
| 2031 | $27.6b | 7.33% |
| 2032 | $24.5b | 11.11% |
EBITDA Margin
| 2024 | 43.47% | 4.43% |
|---|---|---|
| 2025 | 46.24% | 6.36% |
| 2026 | 47.66% | 3.07% |
| 2027 | 48.53% | 1.83% |
| 2028 | 49.93% | 2.88% |
| 2029 | 50.59% | 1.32% |
| 2030 | 43.20% | 14.61% |
| 2031 | 40.72% | 5.74% |
| 2032 | 35.60% | 12.57% |
26 Merck & Co. Analysts have issued a net profit forecast 2025. The average Merck & Co. net profit estimate is $22.6b . This is 29.78% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $23.9b 37.14% , the lowest is $21.7b 24.25% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $17.1b | 4,589.59% |
|---|---|---|
| 2025 | $22.6b | 32.19% |
| 2026 | $24.8b | 9.78% |
| 2027 | $27.6b | 10.95% |
| 2028 | $27.1b | 1.66% |
| 2029 | $25.7b | 5.25% |
| 2030 | $23.3b | 9.36% |
| 2031 | $22.8b | 2.08% |
| 2032 | $23.5b | 3.32% |
Net Margin
| 2024 | 26.68% | 4,293.38% |
|---|---|---|
| 2025 | 34.43% | 29.07% |
| 2026 | 35.73% | 3.78% |
| 2027 | 37.62% | 5.29% |
| 2028 | 36.41% | 3.22% |
| 2029 | 35.63% | 2.14% |
| 2030 | 33.79% | 5.16% |
| 2031 | 33.66% | 0.38% |
| 2032 | 34.20% | 1.60% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
26 Analysts have issued a Merck & Co. forecast for earnings per share. The average Merck & Co. EPS is $8.99 . This is 30.67% higher than earnings per share in the financial year 2024. The highest EPS forecast is $9.50 38.08% , the lowest is $8.61 25.15% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $6.74 | 4,714.29% |
|---|---|---|
| 2025 | $8.99 | 33.38% |
| 2026 | $9.87 | 9.79% |
| 2027 | $10.95 | 10.94% |
| 2028 | $10.77 | 1.64% |
| 2029 | $10.20 | 5.29% |
| 2030 | $9.25 | 9.31% |
| 2031 | $9.06 | 2.05% |
| 2032 | $9.36 | 3.31% |
P/E ratio
| Current | 11.50 | 92.17% |
|---|---|---|
| 2025 | 8.80 | 23.46% |
| 2026 | 8.01 | 8.98% |
| 2027 | 7.22 | 9.86% |
| 2028 | 7.34 | 1.66% |
| 2029 | 7.75 | 5.59% |
| 2030 | 8.55 | 10.32% |
| 2031 | 8.73 | 2.11% |
| 2032 | 8.45 | 3.21% |
Based on analysts' sales estimates for 2025, the Merck & Co. stock is valued at an EV/Sales of 3.41 and an P/S ratio of 3.02 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 3.51 | 40.10% |
|---|---|---|
| 2025 | 3.41 | 2.79% |
| 2026 | 3.23 | 5.45% |
| 2027 | 3.06 | 5.11% |
| 2028 | 3.01 | 1.58% |
| 2029 | 3.11 | 3.28% |
| 2030 | 3.26 | 4.66% |
| 2031 | 3.31 | 1.71% |
| 2032 | 3.26 | 1.64% |
P/S ratio
| Current | 3.11 | 42.37% |
|---|---|---|
| 2025 | 3.02 | 2.74% |
| 2026 | 2.86 | 5.45% |
| 2027 | 2.71 | 5.11% |
| 2028 | 2.67 | 1.59% |
| 2029 | 2.76 | 3.28% |
| 2030 | 2.88 | 4.66% |
| 2031 | 2.93 | 1.71% |
| 2032 | 2.89 | 1.64% |
Current Merck & Co. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Buy
➜
Neutral
|
Downgrade | May 14 2025 |
| Cantor Fitzgerald |
➜
Neutral
|
Initiated | Apr 22 2025 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Apr 17 2025 |
| Deutsche Bank |
Buy
➜
Hold
|
Downgrade | Feb 18 2025 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Feb 12 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Feb 05 2025 |
| BMO Capital |
Market Perform
➜
Market Perform
|
Unchanged | Feb 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Downgrade
Citigroup:
Buy
➜
Neutral
|
May 14 2025 |
|
Initiated
Cantor Fitzgerald:
➜
Neutral
|
Apr 22 2025 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Apr 17 2025 |
|
Downgrade
Deutsche Bank:
Buy
➜
Hold
|
Feb 18 2025 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Feb 12 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Feb 05 2025 |
|
Unchanged
BMO Capital:
Market Perform
➜
Market Perform
|
Feb 05 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
